Key Highlights
- Net loss widened to $40.7 million, or $0.70 per share, from $25.9 million.
- Total operating expenses rose to $42.9 million from $27.7 million.
- FDA extended the Deramiocel PDUFA date to November 22, 2026.
- Shares closed at $6.88, down $0.59, or 8%, at Tuesday's close.
Capricor Therapeutics, Inc. (NASDAQ:CAPR)'s second quarter reflected continued Investment in its Deramiocel regulatory program as the company's net loss widened from a year earlier. Management said it is continuing to work with the FDA on a path forward for the Biologics License Application following a July 29, 2026 advisory committee meeting at which the panel voted 3 in favor and 9 against on whether existing evidence demonstrated substantial evidence of effectiveness for Deramiocel in treating cardiomyopathy in Duchenne muscular dystrophy patients.
CAPR is a biotechnology company developing cell and exosome-based therapeutics for rare diseases, with Deramiocel as its lead program for Duchenne muscular dystrophy. The company said its GMP Manufacturing Facility in San Diego is operational and ready to support an initial commercial launch, contingent on FDA approval, with a second-floor expansion targeted for full validation and FDA inspection in 2027.
Management said programs not directly related to Deramiocel, including its exosome-based platform, are on hold pending further regulatory clarity for Deramiocel.
Second quarter 2026 compared with the prior-year quarter
Total operating expenses were approximately $42.9 million, against approximately $27.7 million. Net loss was approximately $40.7 million, or $0.70 per share, against a net loss of approximately $25.9 million, or $0.57 per share. The company reported no Revenue in either period.
Investment income was $2.2 million for the quarter. Management said the company's accumulated Deficit was $379.6 million as of June 30, 2026.
As part of the BLA review, the FDA conducted a bioresearch monitoring inspection in July 2026 and issued a Form 483 citing one observation, which the company said it has addressed and on which it is awaiting feedback.
Management outlook and stated risks
Management said it submitted an amendment to the BLA that includes 24-month open-label extension data from the Phase 3 HOPE-3 study and additional analyses, requesting that the FDA review the data in support of a refined proposed indication focused on upper limb function, the primary endpoint of HOPE-3. The company said the FDA classified the submission as a major amendment and, in an August 24, 2026 announcement, extended the PDUFA target action date from August 22, 2026 to November 22, 2026.
The company said it has initiated regulatory engagement in Europe and Japan for Deramiocel, and that it withdrew its motion for a preliminary injunction against NS Pharma, opting to resolve the related contractual dispute in arbitration.
Where Things Stand
Management said its primary focus remains advancing Deramiocel toward a potential approval, noting that the therapy has been administered in approximately 1,300 intravenous infusions to more than 200 Duchenne muscular dystrophy patients across three clinical trials. The company said it continues to advance commercial readiness at a measured pace while it awaits the FDA's decision on the amended BLA.






Please wait processing your request...